课题基金 / 基金详情

Mechanisms of action studies of WBI-4002, a novel drug candidate promoting epithelial integrity

Mechanisms of action studies of WBI-4002, a novel drug candidate promoting epithelial integrity
促进上皮完整性的新候选药物 WBI-4002 的作用机制研究
批准号:
543615-2019
负责人:
Stadnyk, Andrew
金额:
$1.82万
依托单位:
依托单位国家:
加拿大
项目类别:
Engage Grants Program
财政年份:
2019
资助国家:
加拿大
项目状态:
已结题
起止时间:
2019-01-01 至 2020-12-31

项目摘要

项目成果

Stadnyk, Andrew的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The cells lining our tissue surfaces in contact with the environment are called epithelial cells. To create a barrier epithelial cells are tightly connected to each other and are sometimes stacked upon each other, like on our skin. In the intestines the epithelium is only one cell thick in order to digest and absorb food. The result is that the "tightness" can be modified by events in the host or from products arriving in the lumen. These changes in "tightness" or integrity occur during diseases like Celiac disease or Crohn's disease and ulcerative colitis. While we understand the molecules involved in epithelial integrity we don't have many products that can improve it when we may need to, but we have some clues from our the food. Certain plants in our diet are thought to have anti-inflammatory and anti-oxidant properties (blueberries, for example). As scientists worked to purify the active plant products "polyphenol stilbenes" were discovered to have health benefits. Welichem Biotech Inc. (Burnaby, BC) has developed a drug in this class they call WBI-4002. WBI-4002 is a trans-hydroxystilbene. They have learned that the drug binds a molecule on the surface of cells called the aryl hydrocarbon receptor (AhR). The AhR is present on many types of cells including on epithelial cells. Other researchers showed that when the AhR binds compatible molecules it can improve the integrity of the epithelium. Welichem Biotech Inc. wants to know if their drug can also modify the integrity of epithelium. The Company contacted Dr. Stadnyk, who is an expert on the intestinal epithelium. Dr. Stadnyk will apply WBI-4002 to intestinal epithelial cells, from humans and mice, in petri dishes, and measure any effects on integrity. He will examine the molecules that make up the bonds between cells to figure out what changes when WBI0-4002 is applied. If the drug works to improve epithelial integrity it may be a good candidate for treating inflammatory diseases of the intestines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of complement in epithelial cell interactions with the gut microbiome
  • 批准号:
    RGPIN-2015-04923
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.19万
  • 财政年份:
    2021
  • 负责人:
    Stadnyk, Andrew
  • 依托单位:
The role of complement in epithelial cell interactions with the gut microbiome
  • 批准号:
    RGPIN-2015-04923
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.19万
  • 财政年份:
    2020
  • 负责人:
    Stadnyk, Andrew
  • 依托单位:
The role of complement in epithelial cell interactions with the gut microbiome
  • 批准号:
    RGPIN-2015-04923
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.19万
  • 财政年份:
    2019
  • 负责人:
    Stadnyk, Andrew
  • 依托单位:
The role of complement in epithelial cell interactions with the gut microbiome
  • 批准号:
    RGPIN-2015-04923
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.19万
  • 财政年份:
    2018
  • 负责人:
    Stadnyk, Andrew
  • 依托单位:
国内基金
海外基金
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
  • 批准号:
    82371028
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵慧
  • 依托单位:
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
  • 批准号:
    82372743
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈卓佳
  • 依托单位:
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
  • 批准号:
    82371054
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郭涛
  • 依托单位:
空气颗粒物通过调控白血病抑制因子参与影响IgA肾病进展的作用与机制研究
  • 批准号:
    82370711
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    谢静远
  • 依托单位: